Yvan Torrente, Marzia Belicchi, Maurilio Sampaolesi, Federica Pisati, Mirella Meregalli, Giuseppe D’Antona, Rossana Tonlorenzi, Laura Porretti, Manuela Gavina, Kamel Mamchaoui, Maria Antonietta Pellegrino, Denis Furling, Vincent Mouly, Gillian S. Butler-Browne, Roberto Bottinelli, Giulio Cossu, Nereo Bresolin
J Clin Invest.
2004;
114(2):182–195
doi:10.1172/JCI20325
This article Copyright © 2004, The American Society for Clinical Investigation
Abstract
|
Full text
|
PDF
D
uchenne muscular dystrophy (DMD) is a common X-linked disease characterized by widespread muscle damage that invariably leads to paralysis and death. There is currently no therapy for this disease. Here we report that a subpopulation of circulating cells expressing AC133, a well-characterized marker of hematopoietic stem cells, also expresses early myogenic markers. Freshly isolated, circulating AC133+ cells were induced to undergo myogenesis when cocultured with myogenic cells or exposed to Wnt-producing cells in vitro and when delivered in vivo through the arterial circulation or directly into the muscles of transgenic scid/mdx mice (which allow survival of human cells). Injected cells also localized under the basal lamina of host muscle fibers and expressed satellite cell markers such as M-cadherin and MYF5. Furthermore, functional tests of injected muscles revealed a substantial recovery of force after treatment. As these cells can be isolated from the blood, manipulated in vitro, and delivered through the circulation, they represent a possible tool for future cell therapy applications in DMD disease or other muscular dystrophies.
